Shujauddin Changi, a chemical engineer, completed his Bachelor’s degree from Institute of Chemical Technology (India) in 2007, followed by a Master’s from Massachusetts Institute of Technology (U.S.A.) in 2008 and a PhD from University of Michigan (U.S.A.) in 2012. He then went on to join Eli Lilly and Co. in their process design and development group. There, Shujauddin utilized his knowledge on process scale-up, modeling & simulation, continuous processing, PATs, and kinetics to successfully lead development and scale-up of various early to late-stage API portfolio projects. Notably, he was actively involved in the built of the first of its kind Small Volume Continuous (SVC) facility (Ireland). His contributions helped successfully manufacture hundreds of kilograms of API through a fully telescoped continuous drug substance route. Shujauddin then expanded his knowledge base working on medium molecule development (peptides and oligonucleotides) leading the innovation and implementation of various technologies for purification all the way from development to commercial scales. In 2019, Shujauddin joined Vertex Pharmaceuticals and is currently leading the development of small molecule drug substance program focused on rare diseases.
With over 12+ years of experience in pharmaceutical industry, Shujauddin has several peer-reviewed publications, book chapters, presentations, and seminars. He is also an active board member of the AIChE PD2M committee and serves as a reviewer for various peer-reviewed journals (e.g. OPRD, I&ECR, etc.). Shujauddin is passionate about innovation and utilizing science and technology to positively impact human life, which is realized through his work. Outside work, he loves Cross-Fitting, reading books, being a foodie, and traveling around the world!